ACE2 expression in allergic airway disease may decrease the risk and severity of COVID-19
AbstractThe coronavirus disease (COVID-19) is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and presents with respiratory symptoms which can be life threatening in severe cases. At the start of the pandemic, allergy, asthma, and chronic obstructive pulmonary disease (COPD) were considered as risk factors for COVID-19 as they tend to exacerbate during respiratory viral infections. Recent literature has not shown that airway allergic diseases is a high-risk factor or that it increases the severity of COVID-19. This is due to a decrease in Angiotensin-converting enzyme 2 (ACE2) gene expression in the nose and bronchial cells of allergic airway diseases. Conventional asthma treatment includes inhaled corticosteroids (ICS), allergen immunotherapy (AIT), and biologics, and should be continued as they might reduce the risks of asthmatics for coronavirus infection by enhancing antiviral defence and alleviating inflammation.
Authors: Rombauts A, Abelenda-Alonso G, Cuervo G, Gudiol C, Carratalà J Abstract INTRODUCTION: Despite adequate antibiotic coverage, community-acquired pneumonia (CAP) remains a leading cause of hospitalization and mortality worldwide. It induces both a local pulmonary and a systemic inflammatory response, particularly significant in severe cases. The intensity of the dysregulated host response varies from patient to patient and has a negative impact on survival and other outcomes. AREAS COVERED: This comprehensive review summarizes the pathophysiological aspects of the inflammatory response in CAP, brie...
Publication date: Available online 10 October 2020Source: American Journal of Kidney DiseasesAuthor(s): Shreeram Akilesh, Cynthia C. Nast, Michifumi Yamashita, Kammi Henriksen, Vivek Charu, Megan L. Troxell, Neeraja Kambham, Erika Bracamonte, Donald Houghton, Naila I. Ahmed, Chyi Chyi Chong, Bijin Thajudeen, Shehzad Rehman, Firas Khoury, Jonathan E. Zuckerman, Jeremy Gitomer, Parthassarathy C. Raguram, Shanza Mujeeb, Ulrike Schwarze, M. Brendan Shannon
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
CONCLUSIONS: This single practice study showed total patient contact was similar over both sample periods, but most contact in 2020 was virtual. Further longitudinal multi-practice studies to confirm these findings and describe future consultation patterns are needed to inform general practice service delivery post-COVID-19. PMID: 33032304 [PubMed - in process]
Publication date: Available online 1 October 2020Source: Academic RadiologyAuthor(s): Neo Poyiadji, Chad Klochko, Jeff LaForce, Manuel L. Brown, Brent Griffith
Curious what people think with pandemic and lack of away rotations.
The pandemic due to the infection by the betacoronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which began in Wuhan, People ’s Republic of China, in December 2019, causing the infectious coronavirus disease 2019 (COVID-19),1 surpassed 21 million infections and more than 700,000 deaths globally,2 with numbers that continue to rise. The prognosis of SARS-CoV-2 infection worsens when comorbidities such as high blood press ure (HBP), chronic obstructive pulmonary disease, diabetes mellitus (DM), cardiovascular disease, and obesity are associated.
Coronavirus disease 2019 (COVID-19) is an acute respiratory syndrome that emerged in the city of Wuhan and rapidly spread throughout the world causing a global pandemic.1 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as its causal agent.1 Factors such as older age or presence of comorbidities are frequently identified as variables with a negative effect on patients ’ prognosis.2 If we focus on the preexistent respiratory conditions, a higher risk of developing a severe infection has been reported in patients with chronic obstructive pulmonary disease.
Coronavirus disease 2019 (COVID-19) is an acute respiratory syndrome which emerged in the city of Wuhan and rapidly spread through the world causing a global pandemic1. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as its causal agent1. Factors such as older age or presence of comorbidities are frequently identified as variables with a negative impact on patients ’ prognosis2. If we focus on pre-existent respiratory conditions, a higher risk of developing a severe infection has been reported in patients with chronic obstructive pulmonary disease3.
Since the first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on January 22, 2020, the number of positive cases and deaths has rapidly increased.(1) The initial report of 140 hospitalized coronavirus (COVID-19) infected patients from Wuhan China indicated that allergic disease, asthma and chronic obstructive pulmonary disease were not risk factors for SARS-CoV-2 infection.(2) However, the clinical features of this condition with cough and shortness of breath might mask, or mimic, an asthma exacerbation.(3) Given the evolving nature of this pandemic, this initial summary may not represent the clinical...